US Stock Futures Decline as Bond Yields Fall Following Reports of Putins Updated Nuclear Doctrine Micron Surges on Report of 1 Trillion Market Cap Milestone SP 500 Edges Higher as Consumer Stocks Offset Energy and Tech Weakness Ferrari Shares Slide Following Unveiling of First Electric Vehicle the Luce Biotech Stocks Face Headwinds but TopTier Names Show Resilience SP 500 and Nasdaq Scale New Peaks as AI Euphoria Lifts Markets Micron Crosses 1 Trillion Mark FirstService Corporation FSV Q1 2026 Earnings Earnings Beat Drives Optimism Yet Shares Edge Lower ROP Q1 2026 Earnings EPS Surpasses Estimates by 258 Amid Solid Operational Performance Rockwell Medical Q1 2026 Earnings EPS Misses Estimates Amid Operational Challenges Traws Pharma Inc TRAW Q1 2026 Earnings BetterthanExpected Losses Highlight Cost Discipline Amid PreRevenue Phase MAC Q1 2026 Earnings BottomLine Miss Weighs on Investor Sentiment ASRV Q1 2026 Earnings Stable EPS at 011 Amidst Flat Market Response Warby Parker Stock Inches Up Navigating Support and Resistance for WRBY BristolMyers Squibb BMY Modestly Declines as Resistance Holds Nuveen Municipal Income Fund NEA Holds Near Key Support After Marginal Advance Cushman Wakefield CWK Faces Selling Pressure Stock Slides 295 Toward Key Support Pyxis Oncology PYXS Shows Resilience with 289 Gain Approaches Key Resistance Twisha Sharma Death Sparks Media Frenzy Over MurderSuicide Claims in India HPK Q1 2026 Earnings Significant Earnings Miss as EPS Falls to 102 SeaStar Medical ICU Gains 195 as Stock Approaches Key Resistance Level OEC Q1 2026 Earnings Significant EPS Miss Amid Positive Stock Reaction GENB Q1 2026 Earnings Wider Loss Stings but Pipeline Progress Lifts Shares Aclarion Inc Q1 2026 Earnings EPS Surpasses Estimates as Company Prioritizes Cost Controls Serina Therapeutics Q1 2026 Earnings EPS Misses Estimates as Stock Climbs Despite Loss enGene Holdings ENGN Q1 2026 Earnings Narrower Loss Than Expected Despite No Revenue UPXI Q1 2026 Earnings Massive EPS Miss Sends Stock Lower DRMA Q1 2026 Earnings NarrowerthanExpected Loss Marks Progress for ClinicalStage Biotech